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Abstract
Purpose Pegfilgrastim is a pegylated form of filgrastim, a
recombinant protein of granulocyte colony-stimulating factor,
that is used to reduce the risk of febrile neutropenia (FN).
Here, we report the results of a phase III trial of pegfilgrastim
in breast cancer patients receiving docetaxel and cyclophos-
phamide (TC) chemotherapy.
Methods We conducted a double-blind, placebo-controlled,
randomized trial to determine the efficacy of pegfilgrastim in
reducing the risk of FN in early-stage breast cancer patients. A
total of 351 women (177 in the pegfilgrastim group and 174 in
the placebo group) between 20 and 69 years of age with stage
I–III invasive breast carcinoma who were to receive TC che-
motherapy (docetaxel 75 mg/m2 and cyclophosphamide
600 mg/m2 every 3 weeks) as either neoadjuvant or adjuvant
therapy were enrolled; 346 of these patients were treated with
either pegfilgrastim (n=173) or placebo (n=173).
Results The incidence of FN was significantly lower in the
pegfilgrastim group than in the placebo group (1.2 vs. 68.8 %,
respectively; P<0.001). In addition, patients in the
pegfilgrastim group required less hospitalization and antibi-
otics for FN. Most adverse events were consistent with those
expected for breast cancer subjects receiving TC
chemotherapy.
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Introduction
Febrile neutropenia (FN) is a potentially life-threatening con-
dition characterized by the development of fever in addition to
chemotherapy-induced neutropenia. With a longer duration of
neutropenia, the risk of contracting FN is greater [1]. FN risk
can be mitigated by reducing chemotherapy dosages or ex-
tending dosing intervals. However, these measures also re-
duce the relative dose intensity of chemotherapy and, conse-
quently, survival rates. Therefore, granulocyte colony-
stimulating factor (G-CSF) is often administered to manage
chemotherapy-associated FN [2, 3] and to allow anticancer
drugs to be administered more effectively. Guidelines for the
use of G-CSF based on the risk of FN have been established
by several groups [4–7]. According to these guidelines, pro-
phylactic G-CSF use is recommended for patients with a clin-
ically significant risk of FN, based on regimen and patient-
specific risk factors.
Pegfilgrastim, a pegylated form of filgrastim, has a long
half-life in circulation. A phase III placebo-controlled, dou-
ble-blind, randomized trial of pegfilgrastim in patients with
breast cancer who received docetaxel in Europe and North
America demonstrated that it significantly reduces the inci-
dence of FN, FN-related hospitalization, and the use of anti-
biotics [8]. Therefore, pegfilgrastim has been approved in
many countries to prevent FN. However, since it has not yet
been approved in Japan, a phase II trial of pegfilgrastim in
breast cancer patients receiving docetaxel, doxorubicin, and
cyclophosphamide chemotherapy was conducted. The trial
demonstrated that pegfilgrastim was safe, and based on the
duration of severe neutropenia, a surrogate endpoint of FN
incidence, 3.6 mg subcutaneous administration once per che-
motherapy cycle is the recommended dose for further devel-
opment [9]. On the basis of these studies, we conducted a
phase III clinical trial of pegfilgrastim in patients with breast
cancer receiving docetaxel and cyclophosphamide (TC) che-
motherapy, a standard treatment regimen for primary breast
cancer [10]. The primary endpoint was the percentage of pa-
tients who developed FN. FN incidence without G-CSF was
also of interest to determine the need for the prophylactic use
of G-CSF, as guidelines commonly recommend such use for
regimens with an FN incidence of ≥20 % [4–7].
Materials and methods
Eligibility criteria
The inclusion criteria were as follows: women aged 20–
69 years, pathological and clinical stage I–III primary invasive
breast carcinoma, Eastern Cooperative Oncology Group per-
formance status 0–2, no prior chemotherapy, absolute neutro-
phil count (ANC) ≥1500/μL, platelet count ≥100,000/μL, he-
moglobin concentration ≥10 g/dL, aspartate aminotransferase
and alanine aminotransferase levels ≤3 times the upper limit of
normal in each institute, total bilirubin level ≤1.5 times the
upper limit of normal, creatinine level ≤1.5 mg/dL, and neg-
ative hepatitis B status. Exclusion criteria were cardiac failure,
a history of radiation therapy within 4 weeks of enrollment,
other concomitant cancers, or bilateral breast cancer. All pa-
tients provided informed consent before study procedures
were performed, and the protocol was approved by institution-
al review boards.
Study design
This was a phase III, multicenter (50 sites), double-blind, pla-
cebo-controlled, randomized trial conducted in Japan. Patients
were stratified by investigational site and chemotherapy status
(neoadjuvant or adjuvant) and then randomized in a 1:1 ratio
using a dynamic allocation method into either the
pegfilgrastim or placebo cohort.
Procedures
All patients received 4–6 3-week cycles of TC chemotherapy.
On day 1 of each cycle, patients were administered docetaxel
(75 mg/m2) and cyclophosphamide (600 mg/m2) intravenous-
ly. If a chemotherapy cycle was delayed bymore than 3weeks,
the patient was withdrawn from the study. If a critical adverse
event (AE) occurred during chemotherapy and a dose reduc-
tion was deemed necessary, the dosage of each drug was re-
duced by 20 % in the next cycle. A dose reduction was
allowed only once.
Pegfilgrastim and placebo were both supplied in vials as
clear, colorless, sterile protein solutions. On day 2 of each
cycle (≥24 h after chemotherapy), patients received a single
subcutaneous injection of either pegfilgrastim (3.6 mg) or pla-
cebo in a double-blind manner. Use of the 3.6 mg dose was
based on findings from Masuda and colleagues, who noted
that the 3.6 mg dose was effective in reducing the incidence of
FN in Japanese patients who received TAC (docetaxel, doxo-
rubicin, and cyclophosphamide) chemotherapy [9]. Patients
who developed protocol-defined FN (defined as an ANC
<500/μL and axillary temperature ≥37.5 °C on the same day
or the following day) were allowed to continue treatment with
pegfilgrastim under open-label conditions.
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The prophylactic use of antibiotics was prohibited until the
first episode of FN was documented. G-CSF treatment was
prohibited; however, rescue treatment was allowed when
protocol-defined FN occurred. Corticosteroids and non-
steroidal anti-inflammatory drugs were also prohibited, except
for AE treatment. However, administration of dexamethasone
by day 3 of each cycle was allowed to counteract side effects
of TC chemotherapy.
Blood samples were obtained from all patients. Complete
blood counts were obtained on days 1, 2, 8, 11, and 15 of the
first cycle; on days 1, 2, 8, and 11 of the subsequent cycles
administered in a double-blind manner; and on days 1 and 2 of
cycles of open-label treatment. Furthermore, at the beginning
and end of the study, serum was analyzed to detect the pres-
ence of antibodies against either pegfilgrastim or filgrastim.
The axillary body temperature of all patients was measured
every day. Patients who were being treated in a double-blind
manner and had an elevated body temperature (≥37.5 °C)
were required to have a complete blood count by the next day.
Efficacy
The primary endpoint was the percentage of patients who
developed protocol-defined FN. Secondary endpoints includ-
ed incidence of FN in the first cycle of chemotherapy, inci-
dence of grade 4 neutropenia, incidence of FN-related hospi-
talization, and percentage of patients treated with antibiotics
for FN.
Safety
Safety assessments were based on AE reports, abnormal lab-
oratory values, and vital signs. AEs were defined by the Jap-
anese version of the Medical Dictionary for Regulatory Ac-
tivities and graded according to the National Cancer Institute’s
Common Toxicity Criteria (version 4.0).
Statistical analyses
The sample size was determined based on the ability to detect
a statistically significant difference with a power of 80 % and
achieve a two-sided significance level of 5 % by the χ2 test.
Based on previous clinical trials, we assumed that 10.3 % of
the patients in the pegfilgrastim cohort and 23 % of the pa-
tients in the placebo cohort would develop FN [9, 11–16]. We
also expected approximately 10 % of all patients to be exclud-
ed or withdrawn from the study. Therefore, target recruitment
was at least 150 patients per cohort.
The primary endpoint was analyzed using the full analysis
set, which included patients who were treated with
pegfilgrastim at least once. Safety assessments were analyzed
using the safety analysis set, which included subjects treated
with pegfilgrastim at least once. Only the data from patients
who were treated in a double-blind manner were analyzed in
terms of efficacy and safety. Secondary endpoints were ana-
lyzed using the χ2 test. All statistical analyses were performed




Between April 2011 and February 2012, 351 Japanese women
with breast cancer were recruited and randomly assigned to
the treatment groups, resulting in 177 patients in the
pegfilgrastim group and 174 in the placebo group. One patient
in the pegfilgrastim group withdrew from the study because
she could not start chemotherapy within 14 days of the screen-
ing test. In addition, three patients from the pegfilgrastim
group and one patient from the placebo group were removed
from the study at the discretion of the investigators, leaving
173 patients in each group (Fig. 1). As shown in Table 1,
patient characteristics were balanced in both groups. Three
patients received an overdose of pegfilgrastim; one patient
randomized to the pegfilgrastim group received 10.0 mg of
pegfilgrastim in the first cycle, and two patients received
10.0 mg in the first and second cycles. These patients were
included in the original full analysis set and safety analysis set.
At the end of the first, second, and third cycles of chemother-
apy, 94, 10, and seven patients in the placebo group, respective-
ly, were permitted to receive open-label pegfilgrastim treatment
after experiencing FN. In contrast, only two patients in the
pegfilgrastim group made this change during this time. No other
changes in patient disposition were observed during the study.
Efficacy
The primary endpoint, the incidence of FN during all cycles of
chemotherapy, differed significantly between the
pegfilgrastim (2/173; 1.2 %) and placebo (119/173; 68.8 %)
Fig. 1 Patient allocation and disposition. FAS full analysis set
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groups (P<0.001) (Table 2). Similarly, differences in other
secondary endpoints were also significant (P<0.05). First,
during the first chemotherapy cycle, FN occurred in one
patient (0.6 %) in the pegfilgrastim group and in 100
patients (57.8 %) in the placebo group (P<0.001). Second,
only seven patients (4.0 %) in the pegfilgrastim group de-
veloped grade 4 neutropenia during all chemotherapy cycles,
whereas all 173 patients in the placebo group progressed to
grade 4 neutropenia during the same time (P<0.001).
Changes in ANC during the first cycle of chemotherapy
are shown in Fig. 2. Third, no patients in the pegfilgrastim
group required FN-related hospitalization, whereas 12/173
patients (6.9 %) in the placebo group did (P<0.001). Fourth,
fewer patients required antibiotics to treat FN in the
pegfilgrastim group (1/173; 0.6 %) than in the placebo
group (98/173; 56.6 %; P<0.001).
Subgroup analysis revealed that elderly patients in the pla-
cebo group tended to have a higher risk than younger patients
for developing FN. Among patients aged <65 years, 66.7 %
developed FN, whereas 88.2 % of those aged ≥65 years de-
veloped FN.
We did not detect any antibodies to pegfilgrastim or
filgrastim in any patient.
Table 1 Summary of
demographic and baseline
characteristics for patients in the
full analysis set (FAS)
ER estrogen receptor, PgR
progesterone receptor, HER2
human epidermal growth factor
receptor 2, SD standard deviation
Pegfilgrastim Placebo
(n=173) (n=173)
n % n %
Age (years) Median 51.0 50.0
Range 26–69 27–69
<65 153 88.4 156 90.2
≥65 20 11.6 17 9.8
Body weight (kg) Mean (SD) 56.0 (9.9) 55.0 (7.6)
<60 123 71.1 131 75.7
≥60 50 28.9 42 24.3
Body surface area (m2) Mean (SD) 1.55 (0.13) 1.54 (0.11)
Chemotherapy Neoadjuvant 24 13.9 22 12.7
Adjuvant 149 86.1 151 87.3
Primary disease Infiltrating ductal carcinoma 158 91.3 153 88.4
Special type 12 6.9 19 11.0
Other 3 1.7 1 0.6
Clinical stage I 64 37.0 56 32.4
II 97 56.1 105 60.7
III 12 6.9 12 6.9
Lymph node involvement pN0 101 58.4 94 54.3
pN (+) 72 41.6 77 44.5
Unknown 0 0.0 2 1.2
Hormone receptor status ER negative 35 20.2 42 24.3
ER positive 138 79.8 131 75.7
PgR negative 60 34.7 60 34.7
PgR positive 113 65.3 113 65.3
HER2 negative 60 34.7 60 34.7
HER2 positive 113 65.3 113 65.3
Table 2 Incidence of febrile neutropenia (FN), FN-related
hospitalization, and use of antibiotics to treat FN in the full analysis set





n % n % P value
Patients with FN 2 1.2 119 68.8 <0.001
Patients with FN-related
hospitalization
0 0 12 6.9 <0.001
Patients treated with antibiotics 1 0.6 98 56.6 <0.001
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Safety
AEs occurred in all patients; however, most were expected
from the chemotherapy regimen, and none were severe
enough to result in death. During the first cycle of chemother-
apy, grade 3 or 4 hematologic AEs were more frequently ob-
served in the placebo group than in the pegfilgrastim group
(Online Resource 1). No patients developed grade 3 or 4
thrombocytopenia or anemia during all chemotherapy cycles.
Non-hematologic AEs occurred in ≥10 % of patients during
the first cycle of chemotherapy (Online Resource 2). Blood
lactate dehydrogenase levels increased, and pyrexia was more
frequent in the pegfilgrastim group than in the placebo group.
After overdosing, drug-related AEs were observed in two pa-
tients during chemotherapy cycles. However, these AEs were
grade 1 and resolved without any treatment.
Regarding bone and back pain, common AEs of G-CSF
treatment, the incidence rates of bone pain in the pegfilgrastim
and placebo groups were 6.4 and 2.3 %, respectively, and the
incidence rates of back pain were 19.1 and 15.0 %, respective-
ly. These AEs were manageable with non-steroidal anti-in-
flammatory drugs. No patients were withdrawn from the study
due to intractable pain.
Discussion
This phase III trial showed that pegfilgrastim reduces the risk
of FN in breast cancer patients who receive TC chemotherapy
by 98 %, consistent with a previous trial that showed that
pegfilgrastim is more effective than placebo in reducing FN
risk in breast cancer patients who receive docetaxel [8]. Our
finding that most FN cases occurred during the first cycle of
chemotherapy is consistent with other studies [8, 17];
therefore, we concluded that pegfilgrastim should be admin-
istered from the first cycle of chemotherapy to achieve effec-
tive FN prophylaxis.
When this trial was planned, the incidence of TC
chemotherapy-induced FN without G-CSF treatment was
controversial. The clinical trial conducted by the US Oncolo-
gy group reported a 5% FN incidence and a 51% incidence of
grade 4 neutropenia [10], while a meta-analysis of 902 pa-
tients treated with TC demonstrated that the pooled estimate
of FN incidence, in the absence of G-CSF, was 29 % (95 %
confidence interval, 24–35 %) [18]. Previous studies in Japan
confirmed these meta-analysis findings, as they showed that
the incidence of FN was >20 % and that of grade 4 neutrope-
nia was >70 % [13, 14]. The definition of FN in terms of body
temperature differs slightly in different countries; for example,
FN is defined as an axillary temperature ≥37.5 °C in Japanese
guidelines and as an oral temperature ≥38.3 °C or 38.0 °C over
1 h in the US guidelines [5, 19]. This difference, however, can
be considered negligible from a clinical point of view and
does not significantly impact the results. Therefore, we select-
ed the percentage of patients who developed FN during all
chemotherapy cycles as the primary endpoint of our trial.
However, the 68.8 % FN incidence in our trial is still much
higher than the incidence observed in the US trial [10]. In
addition, all patients in the placebo group of our trial devel-
oped grade 4 neutropenia. One possible reason for these dif-
ferences may be that patients in these clinical trials did not
undergo hematology tests frequently enough to observe the
ANC nadir. In our trial, patients who were treated in a
double-blind manner were required to undergo hematology
tests on days 8 and 11, when the ANC nadir was expected to
occur, as well as immediately after any occurrence of fever.
Further, ethnic differences may contribute significantly to
such differences, because Asians tend to have a higher risk
of FN than Caucasians [20, 21]. Nevertheless, our results sup-
port the conclusion that the prophylactic use of pegfilgrastim
reduces the FN risk in Japanese breast cancer patients who
receive TC chemotherapy, consistent with current National
Comprehensive Cancer Network breast cancer guidelines that
recommend the use of G-CSF with TC chemotherapy.
We assessed the incidence of FN-related hospitalization
and use of antibiotics to treat FN as secondary endpoints to
evaluate the benefit of pegfilgrastim for outpatient chemother-
apy, which is now common in Japan. However, patients are
required to visit hospitals to receive a shot of G-CSF every day
to alleviate profound neutropenia. Furthermore, hospitaliza-
tion or antibiotic use is required once FN occurs. Our results
indicate that single-administration pegfilgrastim reduces the
need for both FN-related hospitalization and antibiotics to
treat FN; therefore, pegfilgrastim is expected to facilitate out-
patient chemotherapy, reduce hospitalization costs, and im-
prove the quality of life of cancer patients, reducing the burden
of receiving daily administrations.
Fig. 2 Changes in absolute neutrophil counts during the first cycle of
chemotherapy for patients in the full analysis set. Data points and error
bars indicate the mean and standard deviation of 173 measurements,
respectively. The horizontal dashed line marks an absolute neutrophil
count (ANC) of 500/μL. Open circles denote values for the placebo
group, whereas closed circles denote values for the pegfilgrastim group
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Most AEs that occurred in this study were primarily related
to chemotherapy. AEs such as bone pain, back pain, and in-
creased serum lactate dehydrogenase levels were more fre-
quent in the pegfilgrastim group; however, no new safety con-
cerns were identified.
In conclusion, this phase III trial demonstrated that
pegfilgrastim is safe and effective for significantly reducing
FN incidence in Japanese breast cancer patients who receive
TC chemotherapy. We expect that the prophylactic use of
pegfilgrastim will provide numerous clinical and economic
benefits for not only cancer patients but also for cancer treat-
ment in Japan.
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